

1 Development of a novel startle response task in Duchenne 2 muscular dystrophy

3

4 Kate E. Maresh^{1,2}, Andriani Papageorgiou¹, Deborah Ridout^{3,4}, Neil A. Harrison⁴, William
5 Mandy⁵, David Skuse⁶, Francesco Muntoni^{1,2,4*}

6

7 ¹ Dubowitz Neuromuscular Centre, UCL GOS Institute of Child Health, London, UK.

8 ² MRC Centre for Neuromuscular Diseases, UCL, London, UK.

9 ³ Department of Population, Policy & Practice, UCL GOS Institute of Child Health, London,
10 UK.

11 ⁴ NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street
12 Institute of Child Health, University College London, & Great Ormond Street Hospital Trust,
13 London, UK

14 ⁵ Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff,
15 UK.

16 ⁶ Department of Clinical, Educational and Health Psychology, UCL, London, UK.

17 ⁷ Department of Behavioural and Brain Sciences, UCL GOS Institute of Child Health,
18 London, UK.

19 * Corresponding author:

20 Email: f.muntoni@ucl.ac.uk (FM)

21

22 **Abstract**

23 Duchenne muscular dystrophy (DMD), an X-linked childhood-onset muscular
24 dystrophy caused by loss of the protein dystrophin, can be associated with
25 neurodevelopmental, emotional and behavioural problems. A DMD mouse model also

26 displays a neuropsychiatric phenotype, including increased startle responses to threat which
27 normalise when dystrophin is restored in the brain.

28 We hypothesised that startle responses may also be increased in humans with DMD,
29 which would have potential translational therapeutic implications. To investigate this, we first
30 designed a novel discrimination fear-conditioning task and tested it in six healthy volunteers,
31 followed by male DMD (n=11) and Control (n=9) participants aged 7-12 years. The aims of
32 this methodological task development study were to: i) confirm the task efficacy; ii) optimise
33 data processing procedures; iii) determine the most appropriate outcome measures.

34 In the task, two neutral visual stimuli were presented: one ‘safe’ cue presented alone;
35 one ‘threat’ cue paired with a threat stimulus (aversive noise) to enable conditioning of
36 physiological startle responses (skin conductance response, SCR, and heart rate). Outcomes
37 were the unconditioned physiological startle responses to the initial threat, and retention of
38 conditioned responses in the absence of the threat stimulus.

39 We present the protocol development and optimisation of data processing methods
40 based on empirical data. We found that the task was effective in producing significantly
41 higher physiological startle SCR in reinforced ‘threat’ trials compared to ‘safe’ trials
42 ($P<.001$). Different data extraction methods were compared and optimised, and the optimal
43 sampling window was derived empirically. SCR amplitude was the most effective
44 physiological outcome measure when compared to SCR area and change in heart rate, with
45 the best profile on data processing, the least variance, successful conditioned response
46 retention ($P=.01$) and reliability assessment in test-retest analysis ($\rho=.86$). The definition of
47 this novel outcome will allow us to study this response in a DMD population.

48

49

50 **Abbreviations**

51 ASD = Autism spectrum disorder; CS = Conditioned stimulus; DMD = Duchenne muscular
52 dystrophy; ECG = Electrocardiogram; EDA = Electrodermal activity; EEG =
53 Electroencephalography; fMRI = Functional magnetic resonance imaging; GABA = Gamma
54 amino butyric acid; GOSH = Great Ormond Street Hospital for Children; HR = Heart rate;
55 ITI = Inter-trial interval; LOA = Limits of agreement; MEG = Magnetoencephalography;
56 MRI = Magnetic resonance imaging; SCL = Skin conductance level; SCR = Skin
57 conductance response; TTP = Time-to-peak; UCL = University College London; UCL GOS
58 ICH = UCL Great Ormond Street Institute of Child Health.

59 Introduction

60 Duchenne muscular dystrophy (DMD) is a childhood-onset, progressive, life-limiting
61 muscle-wasting disorder, which is frequently associated with complex neuropsychiatric co-
62 morbidities(1). It is an X-linked disorder caused by mutations in the *DMD* gene, which lead
63 to a loss of the protein dystrophin(2). Boys with DMD have long been noted to have a higher
64 prevalence of intellectual disability than the typical population(3, 4). There is also a higher
65 prevalence of other neurodevelopmental disorders such as autism spectrum disorder, attention
66 deficit hyperactivity disorder and emotional and behavioural problems than the typical
67 population(5-9). Whilst several studies have found clinically significant anxiety or
68 internalising symptoms in 23-27% of the DMD participants studied(6-8, 10), anxiety
69 symptoms in DMD have received relatively little attention.

70 The neurobiological basis of anxiety disorders has been extensively investigated in
71 typically developing populations. The ‘emotion’ circuits of the brain involve the amygdala
72 and other deep brain nuclei, as well as connected cortical structures often known together as
73 the limbic system(11). Dystrophin is highly expressed in the amygdala, hippocampus and
74 other limbic structures in humans(12). Several studies have implicated changes in limbic
75 structures resulting from a lack of dystrophin in the pathogenesis of the neuropsychiatric
76 phenotype in DMD. Studies in a mouse model of DMD, the *mdx* mouse, have shown reduced
77 Gamma amino butyric acid-A (GABA_A) receptors in the hippocampus and amygdala(13, 14).
78 In DMD patients there is reduced GABA_A receptor distribution in the prefrontal cortex,
79 which closely interconnects with limbic structures(15). A recent study of resting-state
80 functional magnetic resonance imaging (MRI) found hyperconnectivity in the default-mode
81 network connections between some limbic structures, including the hippocampus, posterior
82 cingulate and precuneus in the DMD group compared to controls(16). Furthermore, *mdx* mice

83 show a behavioural phenotype implicating emotion circuits, demonstrating exaggerated
84 unconditioned ‘freezing’ startle responses compared to wild-type mice when exposed to a
85 threat stimulus, which can be normalised with treatment to restore functional dystrophin(13,
86 17). Therefore, it may be that pathological changes in the emotion circuits due to a lack of
87 dystrophin leads to an increase in anxiety symptoms in DMD, although this has not
88 previously been investigated in humans with DMD.

89 Anxiety in humans is thought to be caused by reactivation of innate fear circuits, and
90 that excessive activation in these circuits could cause pathological anxiety(18). The
91 neurobiology of fear and startle responses has been extensively investigated with behavioural
92 studies in animals and humans using cued fear-conditioning experimental paradigms(19-21).
93 These paradigms use classical fear conditioning to produce associative fear-learning, by
94 pairing a neutral stimulus (conditioned stimulus, CS) with an aversive ‘threat’ stimulus,
95 known as the unconditioned stimulus (UCS), for example a loud noise or low amplitude
96 electric shock. The UCS elicits a behavioural and/or physiological startle or fear response
97 (Fig 1A). Repeated presentation of this pairing leads to a learned association or
98 ‘conditioning’ of the physiological responses to the neutral CS, so subsequent presentation of
99 the CS elicits this conditioned response even without the ‘threat’ UCS. This learned response
100 can subsequently be extinguished with repeated presentation of the CS without the UCS. In
101 discrimination fear conditioning paradigms, two neutral CS are used: a ‘threat’ cue, which is
102 conditioned by the UCS as above (CS+), and a ‘safe’ cue (CS-), which enables comparison of
103 the responses to both cues(22).

104

105 **Fig 1. Schematic diagrams of the discrimination fear conditioning task and individual**
106 **trial protocols.**

107 (A) Trials of two different neutral visual stimuli (coloured squares) called the conditioned
108 stimuli (CS) are presented to the subject in pseudo-randomised trials. One is a ‘threat’ cue
109 (CS+), which is paired with the unconditioned stimulus (UCS), an aversive noise, in the
110 Acquisition phase only. A ‘safe’ cue (CS-) is presented alone with no UCS. The ‘threat’ CS+
111 and ‘safe’ CS- are presented in equal proportions throughout all phases in a pseudo-
112 randomised order. Each block comprises 8 trials, with on average four of each CS per block.
113 In the pre-task calibration phase, no stimuli are presented to allow for baseline skin
114 conductance (SCR) and heart rate (HR) recordings and calibration physiological manoeuvres.
115 The Familiarisation phase (one block) comprises eight CS+/CS- trials presented with no
116 UCS. In the Acquisition phase (three blocks), 10/12 CS+ trials are paired with the aversive
117 UCS (loud white noise) presented binaurally via headphones (~80% reinforcement schedule).
118 After 1-2 hours the Extinction phase is conducted (five blocks), comprising 40 CS+/CS- trials
119 with no paired aversive noise. SCR and HR responses are recorded throughout. (B) Structure
120 of a CS+ trial showing the onset and offset times of conditioned (CS) and unconditioned
121 (UCS) stimuli, and the inter-trial interval (ITI). Each CS+/CS- stimulus is presented for 6s,
122 with onset of UCS after 5s (duration 1s). Both CS and UCS co-terminate 6s into the trial. The
123 ITI begins with a fixation cross for 4s, followed by a neutral picture (black and white
124 drawings of common objects: e.g. house, shoe and car) to maintain attention during the ITI,
125 and ends with a fixation cross prior to commencement of the next trial. The ITI duration is
126 randomised between 13-16s. CS- trials and unreinforced CS+ trials are identical, except for
127 the omission of the UCS. Break periods of 20s occurred between each block of 8 trials.

128

129 Individuals with anxiety disorders have been extensively studied with classical fear
130 conditioning paradigms(23). Physiological startle responses to aversive stimuli in fear-
131 conditioning tasks are typically greater in anxious compared to non-anxious individuals. The

132 degree of acquisition and extinction of conditioned startle responses amongst anxious and
133 non-anxious subjects has varied across paediatric studies, with some showing larger and more
134 persistent conditioned responses in extinction in anxious vs. non-anxious children, and others
135 showing no difference(23-25).

136 Given the increased prevalence of anxiety in DMD and the potential for underlying
137 pathological differences in the emotion circuits in DMD, we aimed to design a novel fear-
138 conditioning task that could be used to investigate startle responses in young males with
139 DMD. These tasks have been used before in paediatric populations, but not in young people
140 with DMD. Given the complex neuropsychiatric profile affecting some people with DMD,
141 there are a number of methodological aspects that are important to take in consideration when
142 developing such a task for this specific population. Indeed, some boys with DMD have
143 sensory processing difficulties, including sensory over-responsivity to loud sounds(26).
144 Sensory over-responsivity can be associated with autism spectrum disorder (ASD) and other
145 neurodevelopmental disorders, which are common DMD comorbidities, and there is some
146 evidence that it is linked to changes in inhibitory GABAergic synapses(27, 28). Most
147 previous studies in children have used auditory stimuli as the UCS, at sound levels ranging
148 from 83-106 dB, rather than an electric shock stimulus (see Supplementary Table 1)(29-31),
149 so the sound level of auditory stimulus would need to be appropriate for participants with
150 possible sensory over-responsivity.

151 Tolerability and drop-out has been a problem in some paediatric studies with more
152 aversive unconditioned stimuli, such as a fearful face paired with a screaming sound, which
153 had drop-out rates of between 10-42% in the non-anxious groups(32-34). Other studies have
154 shown that conditioning can be enhanced by using more salient conditioned stimuli, such as a
155 fearful face as the conditioned stimulus rather than a neutral shape(35) however, this could be

156 a confounding factor in the context of DMD, as impaired facial emotion recognition can be
157 associated with the condition(36).

158 Fear-conditioning studies have employed a number of different physiological
159 outcome measures, which arise from autonomic nervous system reactivity to a ‘threat’
160 presentation and subsequent conditioned responses. The skin conductance response (SCR), a
161 measure of skin sweating, is a well-established and reliable marker of sympathetic activity in
162 fear-conditioning paradigms and is commonly used in both paediatric and adult studies(24,
163 29, 37-40). Other measures used in paediatric studies include fear-potentiated startle and self-
164 reported fear; heart rate and heart rate variability have also been used in adult fear-
165 conditioning studies(39, 41, 42).

166 Heart rate (HR) can either decrease or increase depending on the balance between
167 parasympathetic and sympathetic activity: a short-lasting parasympathetically-mediated
168 bradycardia occurs in both humans and animals in response to threat, typically associated
169 with the freezing response in animals, whilst sympathetically mediated tachycardia arises
170 with conditioning to a given context(42-44). In DMD there is typically a raised resting heart
171 rate and decreased heart rate variability(45, 46), however using HR relative to the baseline
172 may be a useful outcome.

173 The eyeblink reflex in the measurement of fear-potentiated startle measured with
174 electromyography of the orbicularis oculi muscle is another measure of the initial startle
175 response(47), although this measure could be confounded in the DMD population due to the
176 underlying muscle pathology. Pupillary responses, electroencephalography (EEG),
177 magnetoencephalography (MEG) and functional magnetic resonance imaging (fMRI) have
178 also been used in studies in the typical population(48-50).

179 In this protocol-development study we aimed to i) confirm the efficacy of a newly
180 developed fear-conditioning task; ii) optimise data processing procedures; iii) determine the
181 most appropriate outcome measures for the startle response. We present novel fear-
182 conditioning task protocol and its empirical evaluation, firstly in a small group of healthy
183 volunteers, and then in a group of 20 young male DMD and age-matched Control
184 participants. The definition of this novel outcome measure will then allow us to study a DMD
185 patient population for this response.

186 **Materials and Methods**

187 **Recruitment**

188 For the first stage of this task development study, we recruited six healthy volunteers,
189 via advertising at University College London (UCL) UCL Great Ormond Street Institute of
190 Child Health (UCL GOS ICH) from September 2018 to January 2019. Inclusion criteria
191 were: aged 8-25 years; no known neuromuscular disease, mental health diagnosis, cognitive
192 impairment or uncorrected auditory or visual impairment. The study was approved by the
193 UCL Research Ethics Committee (REC) (Project ID no. 9639/001) and was conducted at
194 UCL Great Ormond Street Institute of Child Health.

195 For the second task development stage, we recruited 20 male participants aged 7-12
196 years, half DMD and half age-matched control participants from February to May 2019, with
197 follow-up visits for DMD participants after three months (May to August 2019). Inclusion
198 criteria were: male; age 7-12 years; no significant uncorrected auditory/visual impairment or
199 noise-sensitivity; no neurological/psychiatric diagnosis (Controls only); DMD only -
200 genetically-proven diagnosis of DMD and not receiving ataluren (a dystrophin-modulating
201 therapy targeting nonsense mutations that has the potential to cross the blood-brain barrier).

202 Participants were also asked about visual impairments, including colour-blindness, and
203 whether they experience significant sensory over-responsivity to loud sounds, in which case
204 taking part in the study was advised against.

205 The narrower age range, limiting to pre-pubertal participants, was used for the second
206 stage of the study with DMD and Control participants, as there is evidence in both mouse and
207 humans that age of subject can affect fear responses, with increased responses in adolescence
208 compared to childhood and adulthood(22, 29, 33). Pubertal status was assessed by parents
209 and/or participants using the ‘Growing and Changing’ questionnaire(51).

210 Ethical approval was granted by the Health Research Authority (HRA), London
211 Bridge Research Ethics Committee (18.LO.1575). The study assessments took place at Great
212 Ormond Street Hospital for Children (GOSH) and UCL GOS ICH.

213 **Fear-conditioning task protocol**

214 **Task design**

215 We designed a discrimination fear-conditioning paradigm, which involves two
216 conditioned stimuli (CS)(Fig 1A). One was the ‘threat’ stimulus (CS+) which cued the
217 aversive unconditioned stimulus (UCS), and the other the ‘safe’ stimulus (CS-) which was
218 not associated with the UCS. The CS+/CS- were coloured squares (green and blue) of similar
219 tone and colour depth to make them as similar as possible and with limited prior connotations
220 (e.g. not a typical ‘danger/warning’ colour such as red or orange). Faces were not used to
221 avoid potential bias due to poorer facial effect recognition in some boys with DMD.(36) The
222 CS+ colour (either blue or green) was counterbalanced randomly between participants to
223 avoid any stimulus bias.

224 The auditory aversive unconditioned stimulus (UCS) was a computer-generated white
225 noise of duration 1s at a sound level of 85-90 dB, which is towards the lower end of that used
226 in previous studies (S1 Table) and was chosen as a balance aiming for a sufficiently aversive
227 UCS to elicit physiological startle responses but not so aversive as to cause distress. As a
228 comparison, 90dB is the sound level heard when using a hairdryer, lawnmower or
229 blender(52).

230 The task was divided into four stages, detailed in Fig 1A. During the pre-task
231 calibration period, physiological manoeuvres (deep breath; sudden head turn) and an external
232 stimulus (a loud hand clap) were performed as calibration checks, and neutral images shown
233 in the inter-trial intervals and break periods were presented so participants could habituate to
234 these. In the Familiarisation phase, CS+/CS- were presented with no UCS, allowing
235 participants to also habituate to the conditioned stimuli, and provide baseline measurements
236 of responses to the CS+/CS- alone. In the Acquisition phase, CS+ was paired with the
237 aversive UCS in a partial reinforcement schedule, with 10/12 CS+ trials being reinforced
238 with the UCS and 2/12 unreinforced. Partial reinforcement schedules typically strengthen
239 conditioning responses to the UCS(53). The Extinction phase occurred after a break of at
240 least 1-2 hours and comprised presentation of 40 CS+/CS- trials without the UCS. This
241 enabled measurement of the degree of retention of the conditioned fear response to CS+, and
242 the time taken to extinguish the conditioned response. Due to time constraints it was only
243 feasible to perform the Extinction phase on the same day, although ideally a gap of 24 hours
244 between acquisition and extinction is preferable for stronger retention of conditioned
245 responses(54).

246 A schematic diagram of the structure of a trial is shown in Fig 1B, comprising
247 presentation of one CS (CS+ or CS-), with or without the UCS, followed by a variable inter-
248 trial interval (ITI) that allowed enough time for a return of physiological responses to

249 baseline(38). Simple neutral images were displayed on the screen for part of the ITI to
250 maintain participants' attention, followed by a fixation cross prior to onset of the next trial.
251 Break periods of 20s duration occurred between each block, during which simple written
252 instructions and encouraging comments were displayed on the screen. Where participants
253 found reading difficult, the researcher read out the displayed text.

254 Following the testing of the first two healthy volunteer participants, several changes
255 were made to the task protocol. The trial timings had initially been longer (CS presentation 8
256 s, UCS 2 s, break periods 30 s) and were subsequently shortened as above to improve
257 retention of attention, based on feedback from participants. To further improve attention,
258 neutral images were presented during the ITI and the break periods. In the Extinction phase,
259 the task initially comprised 24 trials (three blocks) based on similar previous studies, however
260 preliminary data suggested that extinction of the conditioned response was not complete by
261 the third block, therefore the Extinction phase was extended to five blocks (40 trials).

262 Test-retest reliability of similar paradigms has been established in healthy
263 individuals(37), however as this was the first such study in a DMD population we invited
264 DMD participants to return for a second visit after three months to repeat the fear-
265 conditioning task to enable test-retest reliability assessment.

266 **Stimulus presentation and event recording**

267 The task was scripted in MATLAB (2017b, Mathworks) using the Psychophysics
268 Toolbox extensions(55, 56). The CS (blue and green squares), UCS (white noise) and text
269 instructions were generated from code within the script. Additional images were presented
270 within the script as .jpg or .gif files. Text instructions were kept as short as possible and in
271 large font, as boys with Duchenne muscular dystrophy can have reading difficulties(57).
272 Digital event markers in the script indicated the start and end of trials, CS and UCS onset,

273 and manually triggered markers for events that may cause non-stimulus-related physiological
274 responses (e.g. cough, talking, deep breath, movement or an external noise). Digital events
275 were recorded using a USB TTL event marking module (BlackBox Toolkit Ltd, Sheffield,
276 UK) to accurately record the timing of these events within the physiological data recordings.

277 Participants undertook the task while seated in a quiet room, either in an outpatient
278 clinic or a research facility. They were seated in front of a laptop computer screen wearing
279 over-ear headphones. Participants were verbally instructed to maintain their focus on the
280 screen and keep still, and that the task included hearing loud sounds which may startle them,
281 and that they could stop the test at any time. The researcher and parent/guardian were present
282 but out of sight of the participant during testing.

283 **Physiological variable data acquisition and processing**

284 The physiological variables recorded were the electrodermal activity (EDA), from
285 which the skin conductance response (SCR) was derived, and the electrocardiogram (ECG).
286 from which heart rate (HR) was derived.

287 Surface skin electrodes were applied to the subject 5-10 minutes before the start of
288 testing to allow the electrode paste to be absorbed into the skin. Two disposable Ag/AgCl
289 surface electrodes pre-filled with isotonic gel were placed on the palmar surface of the 2nd
290 and 3rd digits of the non-dominant hand to record the EDA. Three standard limb ECG
291 electrodes were placed on the torso and wrist. ECG and EDA leads were connected to a
292 Biopac MP160 unit (Biopac Systems, Inc., Aero Camino, CA) and calibrated. EDA and ECG
293 were recorded throughout all phases of the task. EDA data was recorded using a sampling
294 rate of 2000 Hz and a SCR response threshold of $0.01\mu\text{S}$ (37, 38, 58), and ECG data was
295 recorded at a sampling rate of 1000 Hz(59).

296 The sound level of the UCS was checked with an external digital sound level meter
297 prior to each task. The ambient temperature of the room was recorded using a digital
298 thermometer, as this can correlate positively with SCR level, when tested over a range from
299 20-40 °C affect SCR(60). Most Control participants were tested in a research facility room
300 (median temperature 21.0°C; range 18.9-23.3°C), whereas DMD participants were tested in
301 several different clinical settings (median temperature 19.3°C; range 18.3-22.5°C). Whilst
302 there was a significant difference between these values on Mann Whitney U-test comparisons
303 ($U=10.5$, $P=.04$), temperature did not correlate with either baseline SCR ($\rho=0.15$, $P=0.58$)
304 or SCR_{uc} ($\rho=-0.13$, $P=0.66$). Linear regression analysis confirmed that temperature was not
305 a significant predictor of either of these variables.

306 EDA recordings were re-sampled at 15.625Hz and filtered using a 1Hz low pass filter,
307 following Biopac EDA guidelines, to rectify and smooth the data. ECG recordings were
308 filtered using a band pass filter at 1-35 Hz, as per Biopac guidelines, and 2% noise rejection
309 to optimise ECG complex peak detection(59). ECG data was transformed into R-R intervals
310 in seconds, the time intervals between each heartbeat (the ‘R’ indicating the R-wave, which is
311 the maximal positive peak of the ECG complex).

312 **Empirical optimisation of sampling window**

313 EDA data were initially extracted using an automated event-related analysis using a
314 priori sampling windows of 0-10s after CS onset, determined by the timings of stimulus
315 presentation and previously published data on the timings of the latency, peak and recovery
316 time of skin conductance and heart rate responses(38, 40). This was refined empirically by
317 determining the ‘time-to-peak’ (TTP) using the latency and rise-times (time from SCR onset
318 to peak), where $TTP = \text{latency} + \text{rise-time}$ (Fig 2A), to ensure that the time to the SCR peak
319 following UCS-onset time was adequately captured. The mean TTP was longer in the first

320 CS+ trial compared to the remaining trials: mean TTP in the first CS+ trial 13.0s (sd 1.6),
321 mean TTP in remaining trials 8.9s (sd 1.8). By taking the mean plus two standard deviations
322 as an empirical sampling window to ensure maximal capture of outliers, the window would
323 be 12.5s from CS-onset. However, a window >12s would increase the risk of NS-SCRs
324 related to the start of the ITI being captured based on the trial timings. Therefore, to
325 maximise peak detection and minimise the chance of non-specific SCRs being included, we
326 redefined the data extraction window as 0-12s after CS-onset for our paradigm. Manual
327 inspection was still performed for all trials, especially for the first SCR peak, to ensure any
328 outliers were detected but the new window duration optimised peak detection. All EDA and
329 ECG data were re-extracted using this new 0-12s window.

330

331 **Fig 2. Measurement of skin conductance responses.**

332 (A) Schematic diagram of a typical skin conductance response following presentation of the
333 conditioned stimulus, CS. The amplitude of the skin conductance response (SCR_{amp}) is
334 measured from the baseline skin conductance level (SCL_{base}) to the maximum SCL at the
335 peak of the response (SCL_{max}). If artefacts in the data affect SCL_{base} , the minimum SCL
336 before the peak (SCL_{min}) can be used as a baseline measurement instead. Latency is the time
337 from CS onset to the start of the SCR (defined as when the SCR crosses the $0.01\mu S$ detection
338 threshold) and is typically 1-3s. Rise-time is the time from SCR onset to the peak response
339 (SCL_{max}). The ‘time-to-peak’ (TTP) equals latency + rise-time. For the TTP calculations to
340 determine the sampling window, latency was taken from the CS presentation time rather than
341 the UCS (unconditioned stimulus) presentation time. (B)-(D): SCL data from a single
342 participant analysed with automated event-related data extraction. Upper trace (blue) is the
343 tonic skin conductance level (SCL) from which SCRs are measured. Lower trace (pink) is the
344 phasic SCL, used to determine when threshold of $0.01\mu S$ is passed for event-related response

345 identification in the automated analysis. Stimulus onset time (time=0s) indicated by purple
346 arrow/dashed purple vertical line. Orange dashed horizontal line on phasic SCL indicates the
347 0.01 μ S detection threshold. Open parenthesis symbol indicates the start of the SCR when the
348 threshold is crossed. Closed parenthesis symbol indicates the end of the SCR when the phasic
349 SCL drops below 0.01 μ S. ‘Water drop’ symbol denotes the event-related SCR determined by
350 the automated analysis. Dark blue dotted vertical arrows indicate the automated amplitude
351 measurement; Light blue dotted arrows indicate the actual SCR amplitude measurement. **(B)**
352 A typical SCR, which has been correctly identified and measured. **(C)** A non-specific skin
353 conductance response (NS-SCR) starts before CS is presented; a slight hump in the upward
354 NS-SCR indicates where the event-related SCR starts but the automated response
355 measurement (dark blue arrow) overestimates the SCR by measuring the combined amplitude
356 of both responses. This is difficult to accurately re-measure manually so would need to be
357 excluded. **(D)** A typical response starts but as the phasic response (pink line) does not re-
358 cross the 0.01 μ S threshold (orange dashed line) when a second response occurs (e.g. due to a
359 physiological response from a deep breath) the peak of the second response is taken as
360 SCLmax so the automated measurement overestimates the SCR. Responses such as these can
361 be accurately re-measured manually.

362

363 **Data extraction and cleaning**

364 EDA data was extracted from Biopac AcqKnowledge 5.0.3 into Microsoft Excel,
365 using two methods which were then compared: 1) an automated Event-related analysis to
366 linking SCRs to digital event markers for CS+/CS-/UCS presentations; 2) an ‘Epoch’
367 analysis where pre-specified measurement parameters could be set for extraction within a
368 given time window after the digital markers. The EDA is the absolute skin conductance level

369 (SCL) in μS , from which the SCR amplitude (SCR_{amp} , in μS) was derived, the difference
370 between skin conductance level (SCL_{base}) at start of the trial and at maximal response
371 SCL_{max} , i.e. $\text{SCR}_{\text{amp}} = (\text{SCL}_{\text{max}}) - (\text{SCL}_{\text{base}})$, as shown in Fig 2A. The Epoch analysis
372 parameters were: SCL_{base} , SCL_{max} , the minimum SCL in the extraction window (SCL_{min}), the
373 area under the curve of the SCR (SCR_{area} , in $\mu\text{S-s}$). ECG data was also extracted using the
374 Epoch analysis method: the mean R-R interval within the sampling window. Heart rate (HR)
375 in beats per minute (bpm) was derived from the R-R interval using the calculation: $\text{HR} =$
376 $60/\text{R-R}$.

377 Data cleaning involved manual inspection of all SCRs, cross-referencing digital
378 markers. Adjustments to automated measurements were made where the true specific SCR
379 had been incorrectly measured due to artefacts or non-specific SCRs (NS-SCRs) or
380 incorrectly assigned by the automated analysis. Non-specific SCRs (NS-SCR) are
381 physiological responses related to an external or other internal physiological stimulus, or
382 background skin conductance activity. Examples of the manual inspection process are shown
383 in Fig 2. For the event-related analysis, if a non-specific SCR (NS-SCR) started before CS
384 presentation or just after the specific SCR it could merge with the specific SCR leading to a
385 larger, combined response being erroneously measured (Figs 2C and 2D), or the NS-SCR
386 might be the only response recorded if the SCL returned to baseline, and the subsequent
387 specific SCR was disregarded (as only the first response was extracted in the event-related
388 analysis). In some of these cases manual measurements were possible if the initial peak was
389 easily identifiable, but if it was not clear where the true specific SCR started and peaked these
390 data points had to be excluded. For the Epoch-analysis extracted data, if an artefact/NS-SCR
391 just affected the SCL_{base} value a simpler adjustment was often possible instead of manual
392 remeasurement, by measuring the amplitude from the trough value at the start of the response
393 (SCL_{min}) to the maximal response, SCL_{max} , provided that the SCL_{min} was indeed the trough

394 level before the peak, termed a ‘max-min’ switch. Manual remeasurement of SCRs was done
395 in accordance with documented guidelines(37, 60, 61). All manual inspection and
396 remeasurement was performed by a researcher who was blinded to the subject’s group and
397 reviewed by an independent researcher. Non-responders were defined as participants in
398 whom $\geq 50\%$ raw SCRs following UCS presentations and pre-exposure tasks were $< 0.01\mu\text{S}$,
399 based on recommendations from previous literature(40, 62).

400 HR data was cleaned following manual inspection of ECG traces. Very few artefacts
401 affected ECG data, mainly due to body movements, therefore only a small number of data
402 required exclusion. Occasionally R-R intervals were incorrectly measured, if ECG complexes
403 were small, in which case the detection threshold was changed and the analysis re-run to
404 ensure all ECG complexes had detectable R-waves.

405 **Optimisation of data extraction method**

406 We compared both the automated Event-related analysis and Epoch analysis
407 extraction methods to determine which was the most effective method for our data. In the
408 Event-related analysis, the specific SCR is identified from the point at which the SCL first
409 passes the $0.01\mu\text{S}$ threshold on the phasic SCL recording after the digital event marker of
410 interest to the subsequent maximum peak SCL (SCL_{max}), shown in Fig 2. Using the data from
411 four healthy volunteers, we reviewed all SCRs (288 trials) and scored manually for correct
412 detection of SCRs. The Epoch analysis identified significantly more true SCRs than the
413 Event-related analysis (50.3% vs. 34.4%, $\chi^2=15.1$; $P<.001$). We applied both methods to the
414 DMD and Control data from the second stage of the study. Artefacts and NS-SCRs were
415 frequently present in the data and affected both extraction methods, and as such following
416 manual inspection adjustments were required in 38.2% (423/1105) of Event-related analysis
417 trials and 39.1% (417/1067) of Epoch analysis trials (Fig 3B). The data points for the two

418 extraction methods were similar for both study cohorts when represented graphically (Fig
419 3A), although confidence intervals were wider in the event-related analysis in the Acquisition
420 phase, suggesting lower accuracy for this method. The degree of data cleaning was greater for
421 the Event-related extraction method, as time-consuming manual remeasurement was required
422 in more than double the number of trials for the Event-related vs. Epoch method (38.2% vs.
423 16.7%; $\chi^2=126.5$; $P<.001$). The more rapid ‘max-min’ switch was used in the remaining
424 22.3% of Epoch trial adjustments. Data exclusion rates were similar for both methods, with
425 exclusion rates of approximately 9% for both methods in the familiarisation and acquisition
426 phases, and in the extinction phase 18.0% for the epoch analysis and 20.0% for the event-
427 related analysis, reflecting that in the majority of cases the artefacts leading to data exclusion
428 would have affected the data no matter which extraction method was used. The epoch
429 analysis raw data points were slightly closer to the cleaned data than the event-related
430 analysis data points, although not significantly, which also suggests more accuracy with the
431 epoch method (Fig 4). The cleaned SCR data points were very similar for both extraction
432 methods, suggesting that there was good inter-method reliability for the independent manual
433 inspection of the data.

434

435

436 **Fig 3. Comparison of skin conductance response amplitude data derived by Event-**
437 **related and Epoch analysis methods.**

438 (A) Mean skin conductance responses (SCR) in μS from second stage of task development
439 study (DMD and Control participants) in all phases of the fear conditioning paradigm (n=17).
440 SCRs are shown both for analysis using the epoch analysis extraction method (‘Epoch’;
441 circular markers) and the event-related analysis extraction method (‘Event’; triangular

442 markers), for both CS+ and CS- trials. Each data point represents the mean of four CS+ or
443 CS- trials in each block, and error bars indicate 95% confidence intervals. ‘Raw’ data
444 includes all data as extracted using these methods. ‘Clean’ data has excluded data points
445 affected by artefacts, or data points that have been remeasured after manual inspection. FAM
446 = Familiarisation phase; ACQ = Acquisition phase (1-3 blocks); EXT = Extinction (1-5
447 blocks). **(B)** Bar chart indicating percentages of trials included with and without adjustment,
448 and those excluded following manual inspection. ‘Max-min switch’ refers to the use of the
449 minimum skin conductance level (SCL_{min}) value within the trial window where it was more
450 appropriate to use this than the SCL at the trial onset (SCL_{base}). ‘Remeasured’ refers to
451 manual remeasurement, where artefacts prevented automated SCR measurement and a max-
452 min switch was not appropriate or available.

453

454

455 **Fig 4. Comparison of physiological startle response metrics.**

456 **(A)** & **(B)** show comparison of raw and cleaned SCR data for all phases. **(A)** Mean skin
457 conductance response amplitude (SCR_{amp}) for raw (AmplRaw) and cleaned (AmplClean) data
458 by block. Unconditioned SCR startle response taken as the SCRamp on the first CS+ trial
459 (termed ‘ SCR_{uc} ’). **(B)** Mean skin conductance response area (SCR_{area}) for raw (AmplRaw)
460 and cleaned (AmplClean) data by block. Baseline = baseline recordings taken from mean of
461 Familiarisation phase SCR; ACQ = Acquisition phase (1-3 blocks); EXT = Extinction (1-5
462 blocks). **(C)** Change in heart rate from baseline (ΔHR) in Acquisition phase. Baseline heart
463 rate (HR) taken from mean HR in Familiarisation phase. Data points are mean ΔHR for each
464 numbered trial, where ‘+’ denotes a CS+ trial, ‘-’ denotes a CS- trial and ‘^o’ indicates a
465 non-reinforced CS+ trial, i.e. no unconditioned stimulus (UCS) presented. The unconditioned

466 HR startle response metric was taken from the change in HR after first CS+ trial, i.e. from
467 trial '3+' to trial '4-' (termed ΔHR_{uc}). All data were obtained by Epoch analysis extraction.
468 Error bars show 95% confidence intervals.

469

470

471 Overall, we concluded that the Epoch analysis extraction method was superior to the
472 Event-related analysis, given the more rapid and replicable data cleaning, less reliance on
473 potentially subjective manual remeasurement and risks of unblinding and an indication of
474 increased accuracy. It also allowed the SCR area and heart rate data to be extracted in the
475 same process, thus improving efficiency.

476 **Statistical considerations**

477 **Sample size**

478 For the healthy volunteers study the sample size of six participants was selected for
479 pragmatic reasons including time and resources constraints. There is no prior data from a
480 DMD population to base a formal power calculation on. As a guide, a power calculation
481 estimation was performed using healthy paediatric control SCR data from a discrimination
482 fear conditioning study conducted by Gao and colleagues, with mean SCR $0.1\mu S$ and
483 standard deviation $0.075\mu S$ for 8 year old subjects ($n=172$)(31). Taking $0.05\mu S$ as the
484 precision required to detect a clinically significant difference, as in other paediatric studies
485 (31, 63), and $\alpha = .05$, the estimated sample size required for a power of 80% would be 56,
486 with 28 in each group. Previous studies measuring fear responses in anxious/non-anxious
487 children have used total sample sizes of: 35 (group size $n=17/18$)(24); 54 (group size
488 $n=16/38$)(33); 60 (group size $n=8/11/19/16$).(30) Pragmatic considerations potentially

489 limiting the DMD sample size include the fact that is a rare disease with a restricted age
490 range in the inclusion criteria. Furthermore for the purposes of this task development study
491 we were not investigating group differences, therefore we used a sample size of 20, including
492 both DMD and Control subjects, in order to test proof-of-principle which could then be
493 expanded to a larger study to test group differences if we were successful at this stage.

494 **Quantitative variables**

495 SCR amplitude is a well-established outcome measure for fear-conditioning studies,
496 as the SCR response is typically a discrete peak in the EDA recording from which obtaining
497 the amplitude is simple to measure both in automated analysis and manual measurements.
498 Area under the curve has also been proposed a useful measure(64), as it captures the
499 additional information of both the maximal amplitude and the duration of the response rather
500 than just the maximum. A review of the initial data from the healthy volunteer study
501 indicated that both SCR amplitude (SCR_{amp}) and area (SCR_{area}) were potentially useful SCR
502 metrics. The heart rate (HR) responses to stimuli were continuous changes in HR rather than
503 the discrete peaks seen for SCRs, therefore it was not possible to discriminate between CS+
504 and CS- in the same way as for SCR, therefore a differential HR metric was not derived.
505 Instead, the change in the absolute heart rate from the baseline heart rate (ΔHR) was
506 calculated. The measured variables were: 1) SCR_{amp} and SCR_{area} in CS+ trials (SCR_{CS+}) and
507 CS- trials (SCR_{CS-}); 2) Differential SCR, SCR_{Diff} , which is the difference between SCR from
508 contiguous CS+ and CS- trials; 3) Absolute heart rate (HR); 4) Change in HR from baseline
509 (ΔHR), where the baseline was mean HR in the baseline phase for each section of the task
510 (familiarisation phase HR for acquisition trials; pre-extinction baseline phase for extinction
511 trials). As our primary aim was to investigate startle responses, the main outcomes of interest
512 were the initial unconditioned responses to the threat stimulus, which were the initial
513 unconditioned SCR (SCR_{uc}) and the change in HR after the initial threat stimulus (ΔHR_{uc}).

514 Normality checks using Q-Q plots showed approximately normal distributions for
515 SCR_{uc} and Δ HR_{uc}, however on Shapiro-Wilks testing, Δ HR_{uc} failed the normality testing
516 (test statistic for SCR: 0.92, df 18, $P=.13$; test statistic for Δ HR: 0.86, 21 18, $P=.006$),
517 although the small group sizes may have made this assessment inaccurate.

518 **Data analysis**

519 Prior to analysis all subjects were randomly allocated a unique blinding identifier to
520 allow blinded analysis to be conducted. All SCR and HR metrics were plotted and visually
521 inspected as an initial evaluation. For the healthy volunteer analysis, as the task protocol was
522 modified after the first two participants, only the remaining four participants data was used
523 for further comparison.

524 Paired sample *t*-tests were used to evaluate: task efficacy and degree of conditioning
525 (response retention in extinction), based on the difference between SCR_{CS+} and SCR_{CS-}; for
526 any differences in SCR_{uc} and Δ HR_{uc} between Visits 1 and 2. Coefficients of variation (CV)
527 were used to compare outcome measures, where $CV = (sd/mean)*100$. Chi-squared tests
528 were used to compare data extraction methods and pubertal stage, and baseline characteristics
529 of the DMD and Control groups were compared with Mann-Whitney U tests. Spearman
530 correlations and Bland-Altman plots and were used to evaluate test-retest reliability of SCR_{uc}
531 and Δ HR_{uc} metrics. Validity of Bland-Altman plots was confirmed with paired *t*-tests for
532 each data set.

533 **Results**

534 **Participant demographics**

535 In the first task development stage, six participants took part in a healthy volunteers'
536 study. The first two participants undertook the first iteration of the paradigm, following
537 which a review of the data and feedback from these participants was used to make some
538 modifications to the task. Four more participants, all male and aged between 20-25 years old,
539 took part in the final version of the task. All participants were provided with participant
540 information leaflets in advance and gave written, informed consent or assent prior to the
541 study. From an initial data review of the healthy volunteer data, we determined that the task
542 achieved its purpose: it was able to elicit from participants appropriate and recordable
543 physiological responses, particularly event-related skin conductance responses.

544 In the second stage of the task development, we recruited and tested 20 young DMD
545 and Control participants aged 7-12 years old (DMD n=11; Control n=9). All participants and
546 their parents/guardians were provided with age-appropriate participant information leaflets
547 prior to the study and gave their written informed assent or consent respectively. Out of these
548 20, SCR data could not be used in three participants (DMD n=2, Control n=1): one with
549 technical difficulties in the EDA recording, one defined as a 'non-responder' and one with a
550 protocol deviation (the participant stopped and re-started several times) so the data could not
551 be used for either SCR or HR. The final analysis included SCR data from 17 participants
552 (DMD n=9, Control n=8) and HR data from 19 participants (DMD n=11, Control n=8).

553 There was no difference in median age between the groups, and the distribution of
554 pubertal stage scores also did not differ between groups (Table 1). The mean heart rate was
555 significantly higher in the DMD group compared to Controls ($P=.02$), which is a recognised
556 phenomenon in the literature(46), but there was no difference in baseline SCR between
557 groups.

558

559

560 **Table 1: Baseline demographics of DMD and Control participants.**

	Whole cohort					DMD group ^b					Control group				
No. participants, n	20					11					9				
Age, median (range)	10.2 (7.1-12.9)					10.1 (7.1-11.4)					10.4 (8.1-12.9)				
Pubertal stage score	1.0	1.5	2.0	2.5	3.0	1.0	1.5	2.0	2.5	3.0	1.0	1.5	2.0	2.5	3.0
Frequency^a (%)	8/21 (38)	6/21 (27)	3/21 (14)	2/21 (10)	2/21 (10)	5/12 (42)	4/12 (33)	2/12 (17)	1/12 (8)	0/12 (0)	3/9 (33)	2/9 (22)	1/9 (11)	1/9 (11)	2/9 (22)
Baseline SCR, median (range)	0.23 (0.0-0.76)					0.23 (0.01-0.76)					0.23 (0.0-0.49)				
Baseline HR, median (range)	91.3 (70.2-126.5)					95.4 (70.1-126.5); <i>P</i> =.02 ^c					80.1 (70.1-102.1)				

561 Data presented for the whole cohort (n=20) as well as DMD (n=11) and Control groups
 562 (n=9). Median and range presented for variables: age, skin conductance response (SCR);
 563 heart rate (HR).

564 ^aPubertal stage score data shown as frequencies (%) in each category (ranging from 1-5).

565 ^bGroup differences were assessed with Mann-Whitney U-tests (age, baseline SCR and HR)
 566 and Chi-squared test (pubertal stage), with alpha level *P*=.05.

567 ^csignificant difference in baseline HR between DMD and Control groups; *P*=.02.

568

569

570 **Confirmation of task efficacy**

571 Data from both the first healthy volunteer study and the study in young DMD and
 572 Control participants indicated the maximal SCR amplitude (SCR_{amp}) occurred on the first
 573 reinforced CS+ trial, i.e. the initial response to the threat stimulus, and also in the first

574 acquisition phase block (Fig 4A), with significant discrimination between SCR_{amp} in CS+ and
575 CS- trials on first presentation of the threat stimulus, and throughout all Acquisition blocks.
576 This was most marked in block one, ACQ1 (mean difference 2.4 μ S (95%CI 1.6, 3.1);
577 $P<.001$), with the largest difference occurring on the first reinforced CS+ trial (mean
578 difference 4.1 μ S (95% CI 2.6, 5.6); $P<.001$) (Table 2).

579

580

581 **Table 2. Comparison of skin conductance responses in paired CS+ and CS- trials.**

SCR_{CS+} vs. SCR_{CS-}	N	Mean difference (μS)	95% CI	<i>t</i>	Sig., <i>P</i>
1st CS+/CS- ACQ trial pair	16	4.1	2.6, 5.6	5.7	<.001
ACQ block 1	18	2.4	1.6, 3.1	6.9	<.001
ACQ block 2	17	1.7	0.9, 2.5	4.5	<.001
ACQ block 3	16	1.4	0.9, 2.0	6.0	<.001
EXT block 1	17	0.31	.08, 0.54	2.9	.01
EXT block 2	15	0.32	0.05, 0.59	2.5	.02
EXT block 3	13	0.28	0.05, 0.51	2.6	.02
EXT block 4	12	0.17	-0.10, 0.41	1.3	.20
EXT block 5	11	0.16	-0.01, 0.32	2.2	.06

582 Skin conductance responses (SCR) in CS+ and CS- trials were compared for the first trial
583 pair in Acquisition phase, and for the mean of all CS+ and CS- trials in each block (four trial
584 pairs per block) during Acquisition (ACQ) and Extinction (EXT) phases. Statistical
585 comparisons were performed with paired *t*-tests. CS=conditioned stimulus; CI=confidence
586 interval; Sig.=significance, with alpha level =.05. *P*-values <.05 are shown in bold.

587

588

589 To confirm whether conditioning had occurred, we checked for the conditioned
590 response retention when the threat stimulus was no longer presented in CS+ trials in the

591 Extinction phase. There was significant discrimination between SCR_{CS+} and SCR_{CS-} in the
592 first three Extinction blocks ($P=.01$; $P=.02$; $P=.02$; Table 2), indicating that the SCR_{CS+} had
593 been conditioned as it remained higher than SCR_{CS-} . This significant discrimination was lost
594 for the remaining two Extinction blocks, indicating that the conditioned response had
595 extinguished.

596 We have thus confirmed that this new fear-conditioning task achieved the aim of
597 producing physiological responses to the unconditioned stimulus, and successfully
598 conditioning these responses, which could then be extinguished. It also supported the
599 extended Extinction phase that we employed based on preliminary data from the healthy
600 volunteer study.

601 **Evaluation of physiological variables**

602 **Comparing SCR amplitude and area metrics**

603 As well as measuring SCR amplitude (SCR_{amp}) as described above, we also
604 investigated using the area under the phasic skin conductance response curve (SCR_{area}) as an
605 additional exploratory measure, as theoretically this could provide temporal as well as
606 magnitude information(37). Raw and cleaned data for SCR_{amp} and SCR_{area} , shown in Fig 4,
607 indicate that the SCR_{area} metric appeared more accurate than SCR_{amp} for CS+ trial data in
608 Acquisition, but the discrepancy between raw and cleaned data was greater in the Extinction
609 phase for SCR_{area} than SCR_{amp} . However, data cleaning was more time-consuming and
610 potentially subjective and prone to bias for area measurements, due to the higher chance of
611 artefacts and NS-SCR affecting the data within the whole sampling window. Due to these
612 limitations, we concluded that future analysis should use SCR amplitude as the primary SCR
613 metric.

614 **Heart rate metrics: absolute heart rate and change in heart rate**

615 As has previously been established, the mean heart rate was significantly higher in the
616 DMD group compared to the Control group (Fig 5B), therefore evaluation of absolute heart
617 rate between groups was not a useful comparison. It was also not possible to derive a
618 ‘differential’ heart rate, comparing CS+ and CS- trials as HR varied in a continuous way
619 rather than in discrete peaks as seen with SCR, therefore it was more informative to represent
620 the change in HR (Δ HR) compared to baseline, showing all CS+ and CS- trial data in the
621 order presented in the task (Fig 5C).

622

623

624 **Fig 5. Comparison of SCR and HR responses in DMD participants at initial and follow-** 625 **up visits.**

626 Data for n=11 DMD participants who performed the fear-conditioning task at the initial visit
627 (Visit 1) and at a second follow-up visit after 3 months (Visit 2). Paired HR data available for
628 n=11 and paired SCR data available for n=6. **(A)** Mean SCR by block for CS+ and CS- trials
629 over all task phases. Error bars show 95% confidence intervals. **(B)** Paired data for individual
630 participants showing the SCR for the first unconditioned response (SCR_{uc}) in Visit 1 and
631 Visit 2. **(C)** Mean absolute HR by trial in the first Acquisition block. Error bars show 95%
632 confidence intervals. **(D)** Paired data for individual participants showing the Change in HR
633 (Δ HR) from Acquisition trial 3+ to trial 4-, i.e. the unconditioned Δ HR response (ΔHR_{uc}). **(E)**
634 **& (F)**. Bland-Altman Limits of Agreement plots for: **(E)** Unconditioned skin conductance
635 response (SCR; n=6) and **(F)** Unconditioned change in heart rate (Δ HR; n=11). Plots show
636 the mean difference (solid pink line) and upper and lower limits of agreement, LOA, in
637 dashed purple lines. Data labels indicate the values for upper LOA, mean difference and

638 lower LOA (from top to bottom). All data points for both SCR_{uc} and ΔHR_{uc} lie within these
639 LOA boundaries, indicating there is agreement between the test-retest outcomes.

640

641

642 **Unconditioned startle response outcome measures**

643 As our hypothesis concerned measurement of startle responses, we evaluated the
644 unconditioned physiological response metrics to determine the optimal outcome measures for
645 the startle response; firstly how to derive them, and secondly how precise and reliable they
646 were.

647 As the greatest difference in SCR_{amp} between CS+ and CS- trials occurred at the start
648 of the Acquisition phase, we used the SCR amplitude in the first CS+ trial as the
649 unconditioned SCR metric (termed ' SCR_{uc} '). For the optimal HR metric, from inspection of
650 the ΔHR data we determined that there was a reduction in HR after each reinforced CS+ trial
651 in the early stages of the Acquisition phase (Fig 4C), which was largest after the first
652 reinforced CS+ trial. This is a recognised phenomenon known as fear-induced
653 bradycardia(42). We measured the difference in HR after the first reinforced CS+ trial and
654 took this as the unconditioned HR metric (termed ' ΔHR_{uc} ').

655 In Fig 4C it was also evident from the wide confidence intervals for the ΔHR data
656 point after the first CS+ trial (trial 4-) that there was a large variation in ΔHR_{uc} , which might
657 reduce the utility of this as an outcome measure. To determine this more precisely, we
658 calculated coefficients of variation (CV) for each measure. A CV of 100% occurs when the
659 standard deviation of a measure is equal to its mean, and as CV reduces below 100% towards
660 0% this indicates increasing precision(65). The CV for SCR_{uc} was 67.8%, the CV for SCRs

661 in CS+ trials in the first Acquisition block was 56.7% and the CV for ΔHR_{uc} was 103.1%,
662 indicating that the SCR metrics were more precise than the ΔHR_{uc} .

663 To determine test re-test reliability of these outcomes, eleven DMD participants were
664 followed-up at a second visit after an interval of three months. We obtained eleven sets of
665 paired HR data and seven sets of paired SCR data, although one set of SCR data had to be
666 excluded as the participant was a ‘non-responder’ on both occasions (Fig 5). There was a
667 strong positive correlation in SCR_{uc} between visit 1 and 2 (Spearman’s $\rho=0.86$, $P=0.01$, $n=6$),
668 thus meeting our pre-determined criteria for a correlation coefficient of ≥ 0.8 . There was no
669 difference in mean SCR_{uc} between visits 1 and 2 (mean difference 0.19 μS ; 95% confidence
670 interval -1.2,1.6; $t=0.35$, $P=0.73$), or for the remainder of the CS+ and CS- trials in Visit 1
671 compared to Visit 2 on paired t -tests. Individual paired SCR_{uc} data appeared relatively stable
672 values for most participants between visits (Fig 5B).

673 There was no difference in ΔHR_{uc} between visits (mean difference -2.9 bpm; 95%
674 confidence interval -9.6, 3.9; $t=-0.95$; $P=0.37$) (Fig 5C), however, there was more individual
675 variability in this metric (demonstrated on paired data in Fig 5D), and only a moderate, non-
676 significant positive correlation within participants between visits ($\rho=0.42$, $P=0.20$).

677 To further explore reliability, Bland-Altman Limits of Agreement (LOA) plots of
678 difference vs. mean were constructed for both data sets (Figs 5E and 5F). For both SCR_{uc} and
679 ΔHR_{uc} all data points were within the LOA boundaries, indicating agreement in both
680 outcomes on test-retest assessment. However, given the small sample sizes, further study
681 should be done to confirm this.

682 Overall, these results show that SCR_{uc} is a reliable outcome, showing a strong within-
683 subjects correlation at retest, agreement on LOA plot and less variance than ΔHR_{uc} . ΔHR_{uc}

684 also did not show significant test-retest correlation. Therefore, we conclude that SCR_{uc} is the
685 more useful outcome measure for this task.

686 **Discussion**

687 This study presents the development and initial evaluation of a novel fear
688 conditioning task in both healthy volunteers and a clinical population of young males with
689 Duchenne muscular dystrophy and age-matched Control participants. We have shown that the
690 task is effective, have optimised the data processing and analysis methods and have
691 determined physiological startle response metrics which could be studied further as a
692 potential outcome measures in testing the emotion system in children and youth with DMD.

693 These results confirm that the experimental protocol is effective in eliciting
694 physiological unconditioned startle responses, with an increase in skin conductance response,
695 SCR, and decrease in heart rate, HR, following presentation of an aversive stimulus. The
696 SCRs were successfully conditioned to a neutral stimulus, and the conditioned SCRs
697 subsequently extinguished with repeated presentation of the neutral stimulus alone. Thus, this
698 experimental paradigm meets the objectives of the task design.

699 After evaluating of physiological outcome measures, we found that the optimal
700 outcome measure in this paradigm is SCR amplitude. SCR area was effective, but its
701 measurement was prone to more errors and required more data processing and cleaning. By
702 comparing two data extraction methods, we determined the optimal processing pathway for
703 SCR amplitude measurement. We also showed that the unconditioned SCR (SCR_{uc}) metric
704 was reliable on test-retest analysis and was much more precise than the unconditioned change
705 in heart rate ΔHR_{uc} metric.

706 From the heart rate variables, absolute HR and change in HR (Δ HR), Δ HR was the
707 preferred metric due to the group differences in baseline HR between DMD and Control
708 groups. The specific unconditioned Δ HR metric, Δ HR_{uc}, was used to determine the presence
709 of post-threat bradycardia, which is a recognised parasympathetic nervous system response in
710 fearful situations, analogous to the ‘freeze’ response seen in animals(42). However, this
711 metric showed greater variance than SCR_{uc} and did not show significant correlation on test-
712 retest analysis. A further limitation of using heart rate metrics in this context is that DMD is
713 associated with a resting sinus tachycardia from an early age, and decreased heart rate
714 variability as the condition progresses, thought to be related to dysautonomia(46, 66). This
715 may limit the useful comparison of HR metrics between DMD and Control groups.
716 However, HR may provide a useful within-subject outcome measure, as the task elicited a
717 measurable unconditioned response, and recent studies in humans have suggested it can
718 provide a reliable outcome measure(42). Further work using a larger data set should enable a
719 more detailed analysis to determine the optimal HR metric.

720 The main limitations in this study were related to artefacts and data drop-out. The
721 occurrence of physiological artefacts due to external noises may have been reduced if testing
722 had occurred in a soundproof room, which was not available to us for this study although we
723 tried to mitigate this with the use of headphones. Some participants who terminated both
724 phases of the task early (20% in acquisition, 25% in extinction), mostly DMD participants,
725 which led to reduced data especially in the Extinction phase. Feedback from participants
726 indicated that the task was too long, and a minority of participants (mostly in the DMD
727 group) found the noise stimulus too aversive. Therefore, future versions of the task should
728 incorporate modifications to reduce the length of the task and incorporate modified stimuli
729 that will balance aversiveness with the ability to elicit physiological startle responses and
730 produce successful conditioning.

731 In conclusion, this task development study has achieved its aims by confirming that
732 this novel fear-conditioning task is effective in eliciting unconditioned startle responses and
733 successful conditioning and establishing the optimal outcome measures and data processing
734 procedures. These can be applied to future larger studies investigating group differences in
735 startle responses between DMD and Control participants.

736

737 **Acknowledgements**

738 We would like to acknowledge the support of the National Institute of Health Research
739 (NIHR) Biomedical Research Centre at Great Ormond Street Hospital for Children NHS
740 Foundation Trust. The views expressed are participants of the author(s) and not necessarily
741 participants of the NHS, the NIHR or the Department of Health. We thank David Watson
742 (University of Sussex), Charles Marshall (UCL) & Rachael Elward (UCL) for their technical
743 advice in scripting the fear-conditioning task. We gratefully acknowledge the GOSH Somers
744 Clinical Research Facility, the participation of Muscular Dystrophy UK, Duchenne UK and
745 Action Duchenne in promoting study recruitment and all the study participants and their
746 parents/carers.

747 **References**

- 748 1. Snow WM, Anderson JE, Jakobson LS. Neuropsychological and neurobehavioral functioning
749 in Duchenne muscular dystrophy: a review. *Neuroscience and biobehavioral reviews*.
750 2013;37(5):743-52.
- 751 2. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne
752 muscular dystrophy locus. *Cell*. 1987;51(6):919-28.

- 753 3. Dubowitz V. Intellectual Impairment in Muscular Dystrophy. Arch Dis Child.
754 1965;40(211):296-301.
- 755 4. Cotton S, Voudouris NJ, Greenwood KM. Intelligence and Duchenne muscular dystrophy:
756 full-scale, verbal, and performance intelligence quotients. Developmental medicine and child
757 neurology. 2001;43(7):497-501.
- 758 5. Hinton VJ, Cyrulnik SE, Fee RJ, Batchelder A, Kiefel JM, Goldstein EM, et al. Association
759 of autistic spectrum disorders with dystrophinopathies. Pediatric neurology. 2009;41(5):339-
760 46.
- 761 6. Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A, et al. Cognitive and
762 Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy. Journal of child
763 neurology. 2015;30(11):1472-82.
- 764 7. Colombo P, Nobile M, Tesei A, Civati F, Gandossini S, Mani E, et al. Assessing mental
765 health in boys with Duchenne muscular dystrophy: Emotional, behavioural and
766 neurodevelopmental profile in an Italian clinical sample. European journal of paediatric
767 neurology : EJPN : official journal of the European Paediatric Neurology Society.
768 2017;21(4):639-47.
- 769 8. Ricotti V, Mandy WP, Scoto M, Pane M, Deconinck N, Messina S, et al.
770 Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy
771 in relation to underlying dystrophin gene mutations. Developmental medicine and child
772 neurology. 2016;58(1):77-84.
- 773 9. Pane M, Lombardo ME, Alfieri P, D'Amico A, Bianco F, Vasco G, et al. Attention deficit
774 hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-
775 genotype correlation. The Journal of pediatrics. 2012;161(4):705-9 e1.
- 776 10. Pangalila RF, van den Bos GA, Bartels B, Bergen M, Stam HJ, Roebroek ME. Prevalence of
777 fatigue, pain, and affective disorders in adults with duchenne muscular dystrophy and their
778 associations with quality of life. Archives of physical medicine and rehabilitation.
779 2015;96(7):1242-7.

- 780 11. LeDoux J. The emotional brain, fear, and the amygdala. *Cellular and Molecular*
781 *Neurobiology*. 2003;23(4-5):727-38.
- 782 12. Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, PAC TH, Hendriksen JGM, et
783 al. Timing and localization of human dystrophin isoform expression provide insights into the
784 cognitive phenotype of Duchenne muscular dystrophy. *Scientific reports*. 2017;7(1):12575.
- 785 13. Sekiguchi M, Zushida K, Yoshida M, Maekawa M, Kamichi S, Yoshida M, et al. A deficit of
786 brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive
787 behaviour in mice. *Brain : a journal of neurology*. 2009;132(Pt 1):124-35.
- 788 14. Vaillend C, Billard JM. Facilitated CA1 hippocampal synaptic plasticity in dystrophin-
789 deficient mice: role for GABAA receptors? *Hippocampus*. 2002;12(6):713-7.
- 790 15. Suzuki Y, Higuchi S, Aida I, Nakajima T, Nakada T. Abnormal distribution of GABAA
791 receptors in brain of duchenne muscular dystrophy patients. *Muscle & nerve*. 2017;55(4):591-
792 5.
- 793 16. Doorenweerd N, de Rover M, Marini-Bettolo C, Hollingsworth KG, Niks EH, Hendriksen
794 JGM, et al. Resting-state functional MRI shows altered default-mode network functional
795 connectivity in Duchenne muscular dystrophy patients. *Brain imaging and behavior*. 2021.
- 796 17. Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, et al. Functional
797 correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA
798 oligomers. *Nature medicine*. 2015;21(3):270-5.
- 799 18. Gross CT, Canteras NS. The many paths to fear. *Nat Rev Neurosci*. 2012;13(9):651-8.
- 800 19. Fanselow MS. Conditioned and unconditional components of post-shock freezing. *Pavlov J*
801 *Biol Sci*. 1980;15(4):177-82.
- 802 20. Curzon P. R, N.R., Browman, K.E. Cued and Contextual Fear Conditioning for Rodents. In:
803 J.J. B, editor. *Methods of Behavior Analysis in Neuroscience* 2nd Edition. Boca Raton (FL):
804 CRC Press/Taylor & Francis; 2009.
- 805 21. Davis M. The amygdala and conditioned fear. In: Aggleton JP, editor. *The Amygdala:*
806 *Neurobiological Aspects of Emotion, Memory and Mental Dysfunction*. New York: Wiley-
807 Liss; 1992. p. 255–306.

- 808 22. Shechner T, Hong M, Britton JC, Pine DS, Fox NA. Fear conditioning and extinction across
809 development: evidence from human studies and animal models. *Biological psychology*.
810 2014;100:1-12.
- 811 23. Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, et al. Classical
812 fear conditioning in the anxiety disorders: a meta-analysis. *Behaviour research and therapy*.
813 2005;43(11):1391-424.
- 814 24. Waters AM, Henry J, Neumann DL. Aversive Pavlovian conditioning in childhood anxiety
815 disorders: impaired response inhibition and resistance to extinction. *Journal of abnormal*
816 *psychology*. 2009;118(2):311-21.
- 817 25. Shechner T, Britton JC, Ronkin EG, Jarcho JM, Mash JA, Michalska KJ, et al. Fear
818 conditioning and extinction in anxious and nonanxious youth and adults: examining a novel
819 developmentally appropriate fear-conditioning task. *Depression and anxiety*. 2015;32(4):277-
820 88.
- 821 26. Backhouse M, Harding L, Rodger S, Hindman N. Investigating Sensory Processing Patterns
822 in Boys with Duchenne Muscular Dystrophy Using the Sensory Profile. *British Journal of*
823 *Occupational Therapy*. 2012;75(6):271-80.
- 824 27. Wood ET, Cummings KK, Jung J, Patterson G, Okada N, Guo J, et al. Sensory over-
825 responsiveness is related to GABAergic inhibition in thalamocortical circuits. *Translational*
826 *psychiatry*. 2021;11(1):39.
- 827 28. Robertson CE, Baron-Cohen S. Sensory perception in autism. *Nat Rev Neurosci*.
828 2017;18(11):671-84.
- 829 29. Pattwell SS, Duhoux S, Hartley CA, Johnson DC, Jing D, Elliott MD, et al. Altered fear
830 learning across development in both mouse and human. *Proceedings of the National Academy*
831 *of Sciences of the United States of America*. 2012;109(40):16318-23.
- 832 30. Jovanovic T, Nylocks KM, Gamwell KL, Smith A, Davis TA, Norrholm SD, et al.
833 Development of fear acquisition and extinction in children: effects of age and anxiety.
834 *Neurobiology of learning and memory*. 2014;113:135-42.

- 835 31. Gao Y, Raine A, Venables PH, Dawson ME, Mednick SA. The development of skin
836 conductance fear conditioning in children from ages 3 to 8 years. *Developmental science*.
837 2010;13(1):201-12.
- 838 32. Glenn CR, Klein DN, Lissek S, Britton JC, Pine DS, Hajcak G. The development of fear
839 learning and generalization in 8-13 year-olds. *Developmental psychobiology*.
840 2012;54(7):675-84.
- 841 33. Lau JY, Lissek S, Nelson EE, Lee Y, Roberson-Nay R, Poeth K, et al. Fear conditioning in
842 adolescents with anxiety disorders: results from a novel experimental paradigm. *Journal of the*
843 *American Academy of Child and Adolescent Psychiatry*. 2008;47(1):94-102.
- 844 34. Schiele MA, Reinhard J, Reif A, Domschke K, Romanos M, Deckert J, et al. Developmental
845 aspects of fear: Comparing the acquisition and generalization of conditioned fear in children
846 and adults. *Developmental psychobiology*. 2016;58(4):471-81.
- 847 35. Mineka S, Ohman A. Phobias and preparedness: the selective, automatic, and encapsulated
848 nature of fear. *Biological psychiatry*. 2002;52(10):927-37.
- 849 36. Hinton VJ, Fee RJ, De Vivo DC, Goldstein E. Poor facial affect recognition among boys with
850 duchenne muscular dystrophy. *Journal of autism and developmental disorders*.
851 2007;37(10):1925-33.
- 852 37. Boucsein W. *Methods of Electrodermal Recording: Second Edition*. *Electrodermal Activity*.
853 Boston, MA: Springer; 2012.
- 854 38. Dawson ME SA, Filion DL. The Electrodermal System. In: Cacioppo JT TL, Berntson GG,
855 editor. *Handbook of Psychophysiology*. Third ed: Cambridge University Press; 2007.
- 856 39. Dvir M, Horovitz O, Aderka IM, Shechner T. Fear conditioning and extinction in anxious and
857 non-anxious youth: A meta-analysis. *Behaviour research and therapy*. 2019;120:103431.
- 858 40. Lonsdorf TB, Menz MM, Andreatta M, Fullana MA, Golkar A, Haaker J, et al. Don't fear
859 'fear conditioning': Methodological considerations for the design and analysis of studies on
860 human fear acquisition, extinction, and return of fear. *Neuroscience and biobehavioral*
861 *reviews*. 2017;77:247-85.

- 862 41. Marek M, Bigger, J.T., Camm, A.J., Kleiger, R.E., Malliani A., Moss, A.J., Schwartz, P.J.
863 Heart rate variability. Standards of measurement, physiological interpretation, and clinical
864 use. *European heart journal*. 1996;17(3):354-81.
- 865 42. Castegnetti G, Tzovara A, Staib M, Paulus PC, Hofer N, Bach DR. Modeling fear-
866 conditioned bradycardia in humans. *Psychophysiology*. 2016;53(6):930-9.
- 867 43. Klorman R, Ryan RM. Heart rate, contingent negative variation, and evoked potentials during
868 anticipation of affective stimulation. *Psychophysiology*. 1980;17(6):513-23.
- 869 44. Roelofs K. Freeze for action: neurobiological mechanisms in animal and human freezing.
870 *Philos Trans R Soc Lond B Biol Sci*. 2017;372(1718).
- 871 45. da Silva TD, Massetti T, Crocetta TB, de Mello Monteiro CB, Carll A, Vanderlei LCM, et al.
872 Heart Rate Variability and Cardiopulmonary Dysfunction in Patients with Duchenne
873 Muscular Dystrophy: A Systematic Review. *Pediatric cardiology*. 2018;39(5):869-83.
- 874 46. Miller G, D'Orsogna L, O'Shea JP. Autonomic function and the sinus tachycardia of
875 Duchenne muscular dystrophy. *Brain & development*. 1989;11(4):247-50.
- 876 47. Blumenthal TD, Cuthbert BN, Filion DL, Hackley S, Lipp OV, van Boxtel A. Committee
877 report: Guidelines for human startle eyeblink electromyographic studies. *Psychophysiology*.
878 2005;42(1):1-15.
- 879 48. Leuchs L, Schneider M, Spoomaker VI. Measuring the conditioned response: A comparison
880 of pupillometry, skin conductance, and startle electromyography. *Psychophysiology*.
881 2019;56(1):e13283.
- 882 49. Miskovic V, Keil A. Acquired fears reflected in cortical sensory processing: a review of
883 electrophysiological studies of human classical conditioning. *Psychophysiology*.
884 2012;49(9):1230-41.
- 885 50. Sehlmeier C, Schoning S, Zwitserlood P, Pfliegerer B, Kircher T, Arolt V, et al. Human fear
886 conditioning and extinction in neuroimaging: a systematic review. *PloS one*. 2009;4(6):e5865.
- 887 51. Golding J. Growing and Changing: Parent and Son Questionnaire University of Bristol. 1999
888 [Available from: [http://www.bris.ac.uk/alspac/researchers/our-data/questionnaires/puberty-](http://www.bris.ac.uk/alspac/researchers/our-data/questionnaires/puberty-questionnaires/)
889 [questionnaires/](http://www.bris.ac.uk/alspac/researchers/our-data/questionnaires/puberty-questionnaires/).


- 890 52. Amercian Academy of Audiology. Noise Chart; 2010 [Available from: [https://audiology-
web.s3.amazonaws.com/migrated/NoiseChart_Poster-
%208.5x11.pdf_5399b289427535.32730330.pdf](https://audiology-
891 web.s3.amazonaws.com/migrated/NoiseChart_Poster-
892 %208.5x11.pdf_5399b289427535.32730330.pdf).]
- 893 53. Dunsmoor JE, Bandettini PA, Knight DC. Impact of continuous versus intermittent CS-UCS
894 pairing on human brain activation during Pavlovian fear conditioning. *Behav Neurosci.*
895 2007;121(4):635-42.
- 896 54. Maren S. Nature and causes of the immediate extinction deficit: a brief review. *Neurobiology*
897 *of learning and memory.* 2014;113:19-24.
- 898 55. Brainard DH. The Psychophysics Toolbox. *Spat Vis.* 1997;10(4):433-6.
- 899 56. Kleiner M, Brainard, D., Pelli, D., Ingling, A., Murray, R., & Broussard, C. What's new in
900 Psychtoolbox-3? *Perception.* 2007;36(14):1-16.
- 901 57. Hendriksen JG, Vles JS. Are males with Duchenne muscular dystrophy at risk for reading
902 disabilities? *Pediatric neurology.* 2006;34(4):296-300.
- 903 58. Biopac Systems Inc. Skin Conductance Response Analysis 2018 [Available from:
904 <https://www.biopac.com/?app-advanced-feature=skin-conductance-response-analysis>.]
- 905 59. Biopac Systems Inc. ECG Analysis 2018 [Available from:
906 <https://www.biopac.com/knowledge-base/ecg-analysis/>.]
- 907 60. Boucsein W, Fowles DC, Grimnes S, Ben-Shakhar G, roth WT, Dawson ME, et al.
908 Publication recommendations for electrodermal measurements. *Psychophysiology.*
909 2012;49(8):1017-34.
- 910 61. Braithwaite JJ, Watson, D. G., Jones, R., Rowe, M. Guide for Analysing Electrodermal
911 Activity (EDA) & Skin Conductance Responses (SCRs) for Psychological Experiments
912 (Technical Report, version 2.0). Birmingham, UK: Selective Attention & Awareness
913 Laboratory (SAAL) Behavioural Brain Sciences Centre, University of Birmingham; 2015.
- 914 62. Lonsdorf TB, Klingelhöfer-Jens, M., Andreatta M., Beckers, T., Chalkia, A., Gerlicher, A.,
915 Jentsch, V., Mertens, M., Drexler, S., Richter, J., Sjouwerman, R., Wendt, J., Merz C.
916 Navigating the garden of forking paths for data exclusions in fear conditioning research.
917 *PsyArXiv.* 2019.

- 918 63. Fowles DC, Kochanska G, Murray K. Electrodermal activity and temperament in preschool
919 children. *Psychophysiology*. 2000;37(6):777-87.
- 920 64. Bach DR, Friston KJ, Dolan RJ. Analytic measures for quantification of arousal from
921 spontaneous skin conductance fluctuations. *International journal of psychophysiology* :
922 official journal of the International Organization of Psychophysiology. 2010;76(1):52-5.
- 923 65. Lovie P. Coefficient of Variation. *Encyclopedia of Statistics in Behavioral Science*2005.
- 924 66. Thomas TO, Jefferies JL, Lorts A, Anderson JB, Gao Z, Benson DW, et al. Autonomic
925 dysfunction: a driving force for myocardial fibrosis in young Duchenne muscular dystrophy
926 patients? *Pediatric cardiology*. 2015;36(3):561-8.
- 927

928 **Supporting information**

929 **S1 Table. Summary of previously published study designs for fear-conditioning tasks in**
930 **children/youths.** This table presents study protocol details obtained from nine previously
931 published studies using fear-conditioning tasks with paediatric participants, which informed
932 some aspects of the development of the novel task we created for this study. References: ¹Gao
933 Y, Raine A, Venables PH, Dawson ME, Mednick SA. The development of skin conductance fear
934 conditioning in children from ages 3 to 8 years. *Dev Sci*. 2010;13(1):201-12.; ²Pattwell SS, Duhoux S,
935 Hartley CA, Johnson DC, Jing D, Elliott MD, et al. Altered fear learning across development in both
936 mouse and human. *Proc Natl Acad Sci USA*. 2012;109(40):16318-23.; ³Neumann DL, Waters AM,
937 Westbury HR, Henry J. The use of an unpleasant sound unconditional stimulus in an aversive
938 conditioning procedure with 8- to 11-year-old children. *Biol Psychol*. 2008;79(3):337-42.; ⁴Shechner
939 T, Britton JC, Ronkin EG, Jarcho JM, Mash JA, Michalska KJ, et al. Fear conditioning and extinction
940 in anxious and nonanxious youth and adults: examining a novel developmentally appropriate fear-
941 conditioning task. *Depress Anxiety*. 2015;32(4):277-88.; ⁵Field AP. I don't like it because it eats
942 sprouts: conditioning preferences in children. *Behav Res Ther*. 2006;44(3):439-55.; ⁶Lau JY, Lissek


943 S, Nelson EE, Lee Y, Roberson-Nay R, Poeth K, et al. Fear conditioning in adolescents with anxiety
944 disorders: results from a novel experimental paradigm. *J Am Acad Child Adolesc Psychiatry*.
945 2008;47(1):94-102.; ⁷Glenn CR. Comparing electric shock and a fearful screaming face as
946 unconditioned stimuli for fear learning. *Int J Psychophysiol*. 2012;86(3):214-9.; ⁸Jovanovic T,
947 Nylocks KM, Gamwell KL, Smith A, Davis TA, Norrholm SD, et al. Development of fear acquisition
948 and extinction in children: effects of age and anxiety. *Neurobiol Learn Mem*. 2014;113:135-42.;
949 ⁹Schiele MA, Reinhard J, Reif A, Domschke K, Romanos M, Deckert J, et al. Developmental aspects
950 of fear: Comparing the acquisition and generalization of conditioned fear in children and adults. *Dev*
951 *Psychobiol*. 2016;58(4):471-81.



A


Physiological recordings

Electrodermal activity (to derive skin conductance response, SCR)

Electrocardiogram (to derive heart rate, HR)

B



A**B**